DLVR Therapeutics
Toronto
About DLVR Therapeutics
DLVR Therapeutics is a biotechnology company co-founded by University Health Network, the Ontario Institute for Cancer Research and MaRS Innovation. The company is focused on developing a novel, HDL-like Peptide-Phospholipid Scaffold (HPPS) nanoparticle delivery system which selectively targets lipophilic small molecules and siRNA, initially to cancer cells. The company has two principal programs: the first is focused on improving the therapeutic index of known chemotherapeutic drugs; and, the second is focused on the targeted delivery of siRNA. DLVR intends to enter into drug development collaborations with biopharmaceutical partners for both programs.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Funding stage: Seed
- Last round: Seed (Oct 2011)
- Website: dlvrtherapeutics.ca
- Phone: [email protected]
Industries & Categories
Biotechnology, Oncology
Canonical: https://fsome.com/organization/dlvr-therapeutics-2140683 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.